| Literature DB >> 24908308 |
Nicole Salazar1, Daniel Muñoz, James Hoy, Bal L Lokeshwar.
Abstract
In this chapter, we describe a protocol used for stable silencing of chemokine receptor CXCR7 in human cancer cells using shRNA in a lipid transfection setting, previously published by our laboratory. We provide thorough detail and background information about the process of shRNA to clarify the importance of this process. We use CXCR7 shRNA and scrambled sequence shRNA constructs cloned into a pRS plasmid under the control of a U6 promoter for stable expression. Human cancer cells are transfected with shRNA-pRS using Lipofectamine 2000. Cells stably expressing the shRNA are selected from transfected cultures following 2 weeks in medium containing the selection antibiotic puromycin. The emergent cell colonies are evaluated for knockdown of CXCR7 mRNA and protein expression by q-PCR and immunoblotting with rabbit anti-CXCR7 IgG, respectively.Entities:
Mesh：
Substances：
Year: 2014 PMID： 24908308 PMCID： PMC4236910 DOI： 10.1007/978-1-4939-0928-5_19
Source DB: PubMed Journal: Methods Mol Biol ISSN： 1064-3745